Conversely, activation of CLEC7A can exert effective anti-tumor immunity by enhancing the expression of interleukin-33 and interleukin-9 in dendritic cells and by inducing differentiation of naive CD4+T cells into T-helper 9 cells (Zhao et al., 2016; Chen et al., 2018). This evidence concerns the gene IL33 and neoplasm.